Pamrevlumab included in pancreatic cancer action network's adaptive clinical trial platform

San francisco, june 16, 2021 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) announced activation of an experimental arm in the pancreatic cancer action network's (pancan) precision promise sm adaptive trial platform evaluating pamrevlumab [and standard of care] for patients with metastatic pancreatic cancer. the objective of precision promise is to expedite the study and approval of promising therapies for pancreatic cancer by bringing multiple stakeholders together, including academic, industry and regulatory entities.
FGEN Ratings Summary
FGEN Quant Ranking